New targets for Crohn's disease

K Pestell. Trends Pharmacol Sci. 2001 Jul.

. 2001 Jul;22(7):342.

No abstract available

Similar articles

[NOD2 gene mutation associated with susceptibility to Crohn's disease. Evidence of an alteration with links genetic and environmental factors].
Gutiérrez-Ruiz MC, Robles-Díaz G. Gutiérrez-Ruiz MC, et al. Rev Invest Clin. 2001 Sep-Oct;53(5):386-7. Rev Invest Clin. 2001. PMID: 11795102 Spanish. No abstract available.
Human genetics. Tackling common disease.
Todd JA. Todd JA. Nature. 2001 May 31;411(6837):537, 539. doi: 10.1038/35079223. Nature. 2001. PMID: 11385552 No abstract available.
Crohn's gene identified.
Frankish H. Frankish H. Lancet. 2001 May 26;357(9269):1678. doi: 10.1016/S0140-6736(00)04865-0. Lancet. 2001. PMID: 11425381 No abstract available.
Genes, microbes, and T cells--new therapeutic targets in Crohn's disease.
Elson CO. Elson CO. N Engl J Med. 2002 Feb 21;346(8):614-6. doi: 10.1056/NEJM200202213460812. N Engl J Med. 2002. PMID: 11856802 Review. No abstract available.
Inflammatory bowel disease: Crohn's disease and the success of NODern genetics.
Newman B, Siminovitch K. Newman B, et al. Clin Invest Med. 2003 Dec;26(6):303-14. Clin Invest Med. 2003. PMID: 14690304 Review.

Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study.
Romano C, Cucchiara S, Barabino A, Annese V, Sferlazzas C. Romano C, et al. World J Gastroenterol. 2005 Dec 7;11(45):7118-21. doi: 10.3748/wjg.v11.i45.7118. World J Gastroenterol. 2005. PMID: 16437657 Free PMC article. Clinical Trial.